Clinical players and healthcare payers: Aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology

Brett Doble, Paula Lorgelly

Research output: Contribution to journalEditorialOtherpeer-review

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalPersonalized Medicine
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • cancer
  • clinical tumor sequencing
  • cost-effectiveness analysis
  • economic evaluation
  • reimbursement
  • value assessment
  • whole-genome sequencing

Cite this